Project Grant R01CA312218
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $739K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded $237,023 to President and Fellows of Harvard College (operating as Harvard Medical School) on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput tools for tracking the fate of prematurely terminated transcripts in cancer cells. The research addresses alternative polyadenylation (APA) events—post-transcriptional RNA processing mechanisms that drive oncogenesis independent of DNA mutations—across chronic...
- The National Institutes of Health National Cancer Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $274,676 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support translational research on inherited genetic variation in B-cell acute lymphoblastic leukemia predisposition. The funded research dissects the role of common and rare risk variants in the IKZF1 locus, which encodes a key regulator of B-cell...
- The National Cancer Institute awarded Boston Children's Hospital $578,559 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tumor suppressor function of P190 RhoGAP and identify therapeutic vulnerabilities in cancer cells with ARHGAP35 alterations. The research examines how the P190A protein suppresses tumor formation through effects on autophagy and the Hippo signaling pathway. Aim 1 characterizes autophagy defects in cancer cells lacking functional...
- The National Cancer Institute awarded the University of Massachusetts Medical School $622,611 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize CAS9 nickase as a cancer-selective genotoxic agent targeting focal gene amplification in MYCN-amplified neuroblastoma. The project, titled "Creating Cancer-Specific Genotoxicity by Targeting CAS9 Nickase to Focal Gene Amplifications," addresses an unmet medical need in MYCN-amplified...
- The National Cancer Institute awarded Boston Medical Center Corporation $178,000 on June 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop integrated spatial and epigenomic methodologies for mapping gene regulatory networks in triple-negative breast cancer microenvironments. The project combines spatial ATAC-seq, spatial in situ transcriptomics (Xenium), and single-nucleus multiome sequencing from core-needle biopsies to generate high-resolution, patient-specific...
- The National Cancer Institute awarded The Broad Institute, Inc. $694,642 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop live-cell RNA sequencing with single-cell resolution. The project addresses a fundamental limitation in molecular omics measurement: current approaches require cell destruction through lysis, extraction, or fixation to detect molecular contents at high multiplexity, preventing serial measurement of living cells to monitor dynamic processes...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...